GlassScriptPhysician profile
John R Schaub
NPI 1972967792
$8,754.86
in general payments reported to CMS, 2019-2025
64 companies · $2,067 in 2025
The $2,067 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $832 · 2021: $1,533 · 2022: $1,120 · 2023: $981 · 2024: $1,346 · 2025: $2,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,189 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,188.87 |
| Education | $205.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $585.71 | 2019-2023 | Evenity |
| E.R. Squibb & Sons, L.L.C. | $566.86 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $512.44 | 2019-2025 | Monjuvi, Monjuvi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $443.39 | 2019-2025 | Airsupra, Calquence, Imfinzi |
| Astellas Pharma US INC | $435.60 | 2021-2025 | Vyloy, Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $402.94 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $399.57 | 2022-2025 | |
| Beigene USA, INC. | $383.10 | 2021-2024 | Brukinsa |
| Genentech USA, INC. | $356.43 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Janssen Biotech, INC. | $356.41 | 2023-2025 | Darzalex, Erleada, Talvey |
| Eisai INC. | $268.27 | 2020-2025 | |
| Lilly USA, LLC | $260.42 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $254.85 | 2021-2025 | |
| Pfizer INC. | $254.36 | 2019-2025 | |
| Celgene Corporation | $225.29 | 2021-2025 | Reblozyl, Pomalyst |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schaub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.